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Abstract
Pre-exposure prophylaxis (PrEP) is a biomedical intervention that can reduce rates of HIV
transmission when taken once daily by HIV-negative individuals. Little is understood about
PrEP uptake and retention in care among the populations most heavily impacted by the HIV
epidemic, particularly among young men who have sex with men (YMSM) in the Deep
South. Therefore, this study explored the structural, social, behavioral, and clinical factors
that affect PrEP use and retention in care among YMSM in Jackson, Mississippi. Thirty
MSM who were prescribed PrEP at an outpatient primary care clinic were interviewed and
included 23 men who had been retained in PrEP care and seven who had not been retained.
The mean age of participants was 26.6 years. Most (23) participants were African American.
Major factors affecting PrEP use and retention in PrEP care included 1) structural factors
such as cost and access to financial assistance for medications and clinical services; 2)
social factors such as stigma and relationship status; 3) behavioral factors including sexual
risk behaviors; and 4) clinical factors such as perceived and actual side effects. Many partic-
ipants also discussed the positive spillover effects of PrEP use and reported that PrEP had
a positive impact on their health. Four of the seven individuals who had not been retained
re-enrolled in PrEP care after completing their interviews, suggesting that case manage-
ment and ongoing outreach can enhance retention in PrEP care. Interventions to enhance
retention in PrEP care among MSM in the Deep South will be most effective if they address
the complex structural, social, clinical, and behavioral factors that influence PrEP uptake
and retention in PrEP care.
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Introduction
An estimated 1.1 million individuals are living with HIV/AIDS in the United States (US) [1].
Men who have sex with men (MSM) bear a disproportionate burden of the HIV epidemic [2].
Approximately 65% of new HIV infections are attributed to male-to-male sexual contact [3].
HIV incidence continues to increase among MSM, and among Black/African American (AA)
young MSM (YMSM) in particular [2, 4, 5]. AA MSM represent less than 1% of the population
but account for 25% of new HIV diagnoses (5). AA MSM are three times more likely to be
HIV-infected than white counterparts [5].
In 2013, the Southern US accounted for 44% of new HIV diagnoses nationally [6]. Missis-
sippi (MS) ranks 9th highest in rate of new HIV infections [7], and its capital, Jackson, ranks
4th in overall prevalence of HIV [8]. Additionally, Jackson has the highest rate of HIV infec-
tions among MSM [9] and, accordingly, the majority of new infections reported in Jackson are
among AA YMSM [10]. Given this disproportionate burden of HIV, innovative HIV preven-
tion interventions are particularly important to lower the risk of HIV for AA YMSM in the
Deep South, and in Mississippi in particular.
Current HIV prevention approaches have had only modest effects in reducing HIV trans-
mission, particularly among AA MSM. Pre-exposure prophylaxis (PrEP) is a biomedical
approach used to prevent HIV transmission. PrEP can dramatically reduce HIV acquisition,
particularly when patients take medications regularly [11–14]. The implementation of PrEP
has been delivered successfully in diverse clinical settings [15] and its efficacy among MSM,
including AA MSM, has been demonstrated in randomized controlled trials and open-label
studies [16–21]. Recent preliminary analyses from 32 industry sponsored demonstration proj-
ects demonstrate PrEP’s efficacy in real world settings [22]. Until recently, PrEP uptake has
been somewhat limited [23–28], and recent analyses highlight disparities in PrEP uptake [29]
as AA MSM account for a declining number of all PrEP users.
In addition, PrEP is most effective when patients adhere to medications, and adherence
requires retention in PrEP care. PrEP adherence has been studied in the context of clinical tri-
als [11, 30], but little is known about factors associated with adherence or how to enhance
retention in PrEP care in real world settings, particularly for AA YMSM. Barriers to PrEP initi-
ation, adherence and retention in care are complex: structural, social, clinical and behavioral
factors may affect PrEP use [27, 31]. Structural factors shape HIV risk via institutions, the envi-
ronment, access to services and policy. Social factors affect HIV risk through interactions with
others [24, 25, 32, 33]. Individual factors include those that are behavioral or clinical and are
usually related to a person’s decision-making, attitudes, or perspectives. Given the need to bet-
ter understand the factors that may play a role in PrEP uptake and retention in care, particu-
larly among individuals at disproportionate risk of HIV acquisition, this study investigated
social, structural, behavioral, and clinical factors that influence PrEP uptake and retention in
care among a sample of young, largely African American MSM enrolled in a PrEP program in
the Deep South.
Methods
Sample and clinical setting
We interviewed 30 YMSM participating in a PrEP program at a clinic that provides preventive,
primary care, and mental health services for Lesbian, Gay, Bisexual, and Transgender popula-
tions in Mississippi. The clinic also accepts PrEP referrals from a local sexually transmitted
infections (STI) clinic that serves approximately 10,000 patients annually, including 3,000
sexual and gender minorities and 1275 AA MSM. PrEP care at the clinic is provided in
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accordance with Centers for Disease Control and Prevention (CDC) PrEP guidelines [34]. All
participants in the current study were over 18 years of age, spoke and read English, and pro-
vided written informed consent. We interviewed 30 individuals retained in PrEP care as well
as individuals who had not been retained in care. The University of Mississippi Medical Cen-
ter’s Institutional Review Board approved this study.
Data collection
Semi-structured interviews lasted approximately 45 minutes and assessed structural, social,
behavioral, and clinical factors that may have affected individuals’ uptake, adherence, and
retention in PrEP care. We used a purposeful sampling strategy; all participants were recruited
after being prescribed and enrolling in the PrEP program. At the time of the interview, 25% of
the sample had stopped taking PrEP or never filled their prescriptions. We phoned partici-
pants who had been lost to follow up care as many as five times to try to understand why they
had discontinued PrEP. Interviews were conducted by trained qualitative researchers and con-
ducted in a private room. Each participant received a $30 gift card. All interviews were digitally
recorded and later transcribed. In accordance with grounded theory, we interviewed partici-
pants until we reached saturation, when no new data were being discovered.
Data analysis
A general inductive approach guided the analysis of data, which allowed for the data to be for-
mulated into themes and categories [35]. Coders read the transcribed data for participant
responses that were similar and recurrent themes and patterns in the transcripts. Open and
axial coding were then used to outline concepts among three coders. Each theme and sub-
theme was assigned a code, and the codes were compiled in a codebook [36]. Quality checks
were conducted on 20% of all transcripts via iterative coding by at least two coders. Discrepan-
cies in interpretation were resolved among the research team before final coding commenced.
Results
Demographic characteristics
The mean age of participants was 26.6 years (SD = 8.2) and all participants were male. Most
participants were AA (n = 25) and all reported being MSM. Most participants (n = 23) utilized
the industry sponsored medication assistance program to help pay for PrEP medications; this
program is only available to individuals who are uninsured and of low socioeconomic status.
Seven of the 25 participants had not been retained in PrEP care and had discontinued taking
PrEP. Among these individuals who had discontinued PrEP, more than half (n = 4) returned
to PrEP care after their interview.
Across interviews, key themes emerged related to structural, social, behavioral and clinical
factors that influenced PrEP use and retention in care (see Table 1). Structural factors affecting
PrEP use included perceived limited access to payment assistance programs and concerns
about costs of medications and clinical services. Social factors included HIV stigma and rela-
tionship status. Finally, behavioral factors included sexual risk behaviors and clinical factors
included concerns about actual and perceived medication side effects. In addition, many indi-
viduals also reported positive spillover effects related to PrEP use; for example, several noted
they felt more empowered to control their sexual decision-making and were more cognizant
of their HIV acquisition risks than they were before starting PrEP.
Social, structural, behavioral and clinical factors influencing PrEP retention
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Structural factors
Many participants indicated that structural factors such as cost, assistance with medical visit
and medication payments affected their experiences taking PrEP. While many participants
noted that they had initially perceived the high cost of PrEP as a potential barrier to use, those
barriers were overcome with the industry sponsored medication assistance program, which
pays for PrEP for uninsured patients and provides assistance with medication copayments for
insured individuals. One participant explained: “It [the medication assistance program] covered
most of my co-pay when I initially started PrEP.” When asked how much participants would be
willing to pay for PrEP, most participants reported they would be unable to pay for PrEP out
of pocket, and would not be able to take PrEP if the medication cost were not subsidized. For
instance, a participant stated: “I wouldn’t pay more than fifty dollars. I probably would not be
able to afford to pay out of pocket.” Another participant reported that he had lost his job and
health insurance, and because he did not know about the medication assistance program, he
discontinued using PrEP:
“When I first started PrEP the doctor told me, I had to have insurance. At that time, I did have
insurance, but when I switched jobs, I lost that insurance and it took a while to get it back.
And when I went back to talk to her again, she said it was free now, so, but I never got up to
talk to her again about restarting it.”
Social factors
Social factors including participants’ relationship dynamics, their partners’ HIV serostatus and
PrEP-related stigma also affected PrEP use and retention in care.
Relationship status and partner’s HIV status. Many participants stated that they
believed they might not need PrEP while engaged in long-term monogamous relationships. A
participant said: “The only people that should be takin’ it are people who are not married, so
when I get married, I shouldn’t have that problem, but up until that point, I will [take PrEP].”
Other participants reported that they began using PrEP when they commenced a new relation-
ship with someone who was HIV positive. One participant stated: “I was in a relationship with
someone that was positive, and I’m negative. We didn’t really use condoms all the time. . .and I
got tested habitually but just so we could cover our bases, I decided to go on PrEP”. Another par-
ticipant noted how both medication cost and his relationship status affected his decision to
continue taking PrEP:
Table 1. Primary results summarized.
Broad Factors Affecting PrEP Use Themes and Quotes
Structural Factors • Access to payment assistance programs
• Copayments and deductibles for Medications and related services
Social Factors • HIV stigma and homophobia
• Relationship status changes
Behavioral Factors • Changes in sexual risk behaviors
Clinical Factors • Perceived and actual medication side effects
Positive Spillover Effects • Enhanced sexual health literacy
• More agency in sexual decision-making
doi:10.1371/journal.pone.0172354.t001
Social, structural, behavioral and clinical factors influencing PrEP retention
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“Who knows, maybe [I’ll be on PrEP] forever. Like I said, it depends on cost. I’m sure it’ll
decline in cost over the years and there will be a generic out in probably ten years, There are
things that will happen that will make it more affordable for more people in the future, but
that’s hard to say. I may become monogamous. I doubt it, but. . .”
PrEP- related stigma. While most participants reported that they did not experience any
external stigma related barriers to PrEP uptake, many stated that they worried about antici-
pated stigma from various sources. For instance, one participant was concerned about his
parents noticing fees for PrEP-related medical services on his insurance statement. He stated:
“I was a bit worried about my insurance and my parents seeing it on my insurance bill, but
then they had this little card that helps cover the cost that the insurance doesn’t pay for, and it
doesn’t necessarily show up as PrEP that you’re taking on your insurance. So once I got over
that, I was comfortable with taking it.”
Other participants relayed that they were concerned about their religious communities dis-
covering they were taking PrEP. A participant who discontinued PrEP stated: “Now I feel I just
want to be honest to be myself. Why I didn’t take those pills? Because of my church, I think.”
Additionally, some participants were concerned about how their sexual partners might
react to them taking PrEP. For instance, one participant worried that his partner would ques-
tion the trust in their relationship if he found out about his PrEP use: “I was worried it might
upset my partner that I was taking it because you should trust each other.”
Another participant who discontinued PrEP noted that he had returned to attending reli-
gious services and decided not to have sex with men in the future, citing that he no longer
needed PrEP.
Behavioral factors
In addition to structural and social factors, many participants cited behavioral factors that
influenced their PrEP use, such as sexual risk behaviors. Some mentioned they met anony-
mous partners online or had multiple sexual partners, and that these actions resulted in their
consideration of PrEP use. One participant stated: “I did [meet partners online]. That is the first
time I did. That’s what I did and it really hurt me bad. . ..I met someone online, and we performed
unsafe sex. And I worry about my status every day. Every single day. I never stop worrying about
that.” Other participants stated that they started taking PrEP because they were having sex
with multiple people. For instance, one participant reported: “I got on PrEP because I thought it
was really beneficial for me because having sex with multiple sex partners was putting me at risk.”
Clinical factors
Most participants reported no side effects or clinical challenges associated with PrEP use; only
two participants experienced or perceived side effects that prompted them to discontinue
PrEP. For instance, one participant reported stopping PrEP after experiencing nightmares:
“I was having nightmares. I wasn’t experiencing these until I started PrEP, but I think it was
because it was like stress plus the side effects, which made it worse. I didn’t like it. It was fine
taking a pill every day. I always stayed on task. I took it at the same time every day, but
[because of the nightmares] it wasn’t fitting.”
Social, structural, behavioral and clinical factors influencing PrEP retention
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Another participant noted: “The only side effect that I experienced was a bad headache when
I first started takin’ it, and being nauseous. It lasted for the whole day. But After I took it [PrEP]
the first time I stopped.”
Still, anticipated side effects were a major concern for many participants, and for some,
were a factor undermining retention in PrEP care. One participant said: “As long as we con-
tinue to determine that there are no side effects, I’ll continue. But I worry about my liver, I worry
about my kidneys.”
Positive spillover effects of PrEP uptake
Many participants noted the positive impacts taking PrEP had on their overall and sexual
health. Many reported that taking PrEP had prompted them to be more discerning when
choosing their sexual partners. One participant stated: “I’m more cautious [about picking my
partners] now.” In addition, some participants reported discussing risk reduction practices
more with their sexual partners after they commenced PrEP. One participant reported: “I feel
safer when doing it [having sex], and it has made me more aware when it comes to my sexual
habits. I ask more questions now.” Most participants reported that they did not change their
risk behaviors after commencing PrEP; most reported either no change or an increase in con-
dom use after starting PrEP. A participant stated: “I really feel like I’ve won my life back. I don’t
want to put my life at risk anytime again, and the doctor told me I can take this pill, but I still
need to have safe sex.” One participant also noted that taking PrEP allowed him to continue to
enjoy sex: “As long as I take these pills, I can still enjoy sex.”
Opportunities for re-engaging patients in PrEP care
Finally, interviewing individuals who had fallen out of PrEP care prompted four participants
to re-engage in PrEP care. One participant previously unaware of the medication assistance
program enrolled in the program after his interview. Another participant in a serodiscordant
relationship who had discontinued PrEP also underwent HIV testing the same day as the inter-
view, and ultimately re-engaged in PrEP care. These success stories suggest that individuals
who are lost to PrEP care can often be re-engaged in PrEP care.
Discussion
To our knowledge, this is among the first studies to explore the lived experiences of YMSM
prescribed and taking PrEP in the Deep South. Our findings suggest that structural factors
such as insurance, costs and copayments as well as social factors such as relationship dynamics
and stigma impacted PrEP uptake and retention in PrEP care. Behavioral factors including
sexual risk behaviors and clinical factors such as actual and perceived side effects also affected
participant’s decisions about starting and continuing to take PrEP. Additionally, participants
reported many unintentional positive, health-related spillover effects of taking PrEP and many
of the MSM who had discontinued PrEP use re-initiated after participating in this study.
Our results echo findings from other studies related to the barriers and facilitators of PrEP
programs [37–40]. A recent qualitative study including 24 predominately AA MSM in Los
Angeles also demonstrated that stigma affected PrEP initiation and adherence [37]. Recent
research by Philbin and colleagues also highlighted stigma as a possible multi-level factor that
can affect attitudes and uptake of PrEP among AA MSM [31]. Participants in the this study
were recruited from New York City, and the social stigma associated with identifying as MSM
in the Deep South may be even greater.
Previous research has also found that perceived cost may be a barrier to PrEP uptake. For
instance, a 2013 study reported that many YMSM believed they would not be able to afford
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PrEP if they lacked insurance coverage [24]. Although, another recent study found that actual
cost of PrEP was not a factor that affected PrEP retention in care [41]. Perceived and actual
costs of both PrEP medications and clinical visits undermined retention in PrEP care in the
current study. Although most participants utilized the medication assistance program that
helped pay for PrEP care, many worried about being able to continue on PrEP if the financial
assistance not available. Finally, individual sexual risk behaviors also influenced PrEP uptake
and adherence in this population, as in other studies [40].
Findings from this study suggest that structural, social, behavioral and clinical factors
should be considered when designing and evaluating PrEP programs focused on engaging AA
YMSM in the Deep South. Additionally, patient education that includes detailed information
about patient assistance programs and the possible side effects of PrEP would likely enhance
PrEP uptake. This strategy aligns with previous literature that highlights the need for public
policy and social marketing sources to address stigma associated with PrEP use in order to
promote PrEP uptake and retention in PrEP care [42, 43]. In the Deep South, stigma related to
sexual orientation and sexual behavior may pose challenges to PrEP uptake and retention in
PrEP care; social marketing, public policy and PrEP programs should respond to these contex-
tual challenges.
It is also noteworthy that over half of the individuals who had discontinued PrEP care indi-
cated that they were interested in taking PrEP again after their interview. This demonstrates
the importance of consistent outreach for individuals enrolled in PrEP programs, particularly
those who are not retained in care, as well as the opportunity to re-engage patients with case
management services. Intensive case management that assists patients with overcoming barri-
ers to care has proven effective for individuals living with HIV and at-risk groups [44–47].
Finally, novel in our findings is that many participants reported being more attuned to
their health and well being after starting PrEP. Participants stated that they were “more cau-
tious”, “more aware”, and had won “their life back” and many engaged in less condomless sex
while on PrEP. This positive spillover effect of PrEP use has implications for practice. For
instance, those who successfully initiate PrEP could act as PrEP peers to educate other at-risk
groups about the cascading effect of PrEP use on general well being. The dissemination of this
knowledge could help eliminate known PrEP uptake barriers and social stigma specifically
linked with PrEP use.
Limitations
This study is subject to several limitations. While we interviewed some patients who were not
retained in PrEP care, several others were completely lost to follow up and were not included
in our sample. Our findings may therefore not represent the experiences of all patients who
were not retained in care, or the broader US. Our study does present important findings iden-
tifying barriers to uptake and retention in PrEP care for individuals who are among the highest
risk for HIV acquisition in the US.
Conclusion
Addressing structural factors such as cost or access to payment assistance programs, social fac-
tors such as stigma and relationship dynamics, and clinical and behavioral factors such as
anticipated or experienced side effects of PrEP medication and sexual risk behaviors is impera-
tive. With persistent outreach, we were able to re-engage several patients in PrEP care who had
previously been lost to follow-up, suggesting that barriers to retention in PrEP care can be
overcome in the Deep South. Future research to promote PrEP uptake and retention in care
should address social, structural, behavioral and clinical factors.
Social, structural, behavioral and clinical factors influencing PrEP retention
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